Quote:When he was at Mayo he asked his onco about getting approved for Leronlimab. She dismissed it saying his cancer has not progressed far enough yet (I think it has been five and a half years since he was diagnosed so not sure what constitutes far enough progression). She basically told him he is not close enough to death to consider an unapproved treatment.
Unapproved does not mean ineffective. If they wait around until he's at death's door it may be too late. There are hundreds if not thousands of medical white papers on CCR5 and cancer. Did she decide to stop learning anything new after she left University? At the very least she should look at the recent abstract from the AACR on mTNBC. She would then realize the mechanism of action and that it is universal among cancers.
In most cases that I recommended leronlimab the patient decided to just follow the doctor's advice. In one the doctor enrolled the patient in a trial for a different drug that failed and another numerous doctors refused to consider it but the patient was in very bad shape. All those patients are now deceased.
In the latest one the patient has opted for a double mastectomy if the tumor is not metastatic, if it is metastatic she may consider it. She is HER2 negative but not triple negative so not eligible for the upcoming mTNBC trial.
Leiomyosarcoma seems to have no history of studies with CCR5 inhibitors, no surprise given its rarity. What is known is that Leiomyosarcoma's are generally cold tumors with low PD-L1 expression, a large amount of tumor associated macrophages (tumor protectant), inflammatory response profile, low T-cell levels. A definite sign of immune dysregulation. A lower CCR5 expression than solid tumors in the tumor itself but elevated CCR5 expression on the surrounding soft tissue. Given the immune suppression profile, I think leronlimab would be useful against the tumor itself and the often accompanying metastasis. The downside is that with no history of studies with CCR5, physicians may be even more reluctant to use leronlimab.
12
